Onconova Therapeutics, Inc. (ONTX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ONTX
- Company Onconova Therapeutics, Inc.
- Price $25.77
- Changes Percentage -12.14
- Change -3.5609
- Day Low $24.65
- Day High $26.53
- Year High $1.45
- Year Low $0.55
- Market Cap $20,904,684
- Price Avg 50 EMA (D) $0.82
- Price Avg 200 EMA (D) $0.78
- Exchange NASDAQ
- Volume 1,254,618
- Average Volume 126,338
- Open $26
- Previous Close $29.33
- EPS -0.96
- PE -1.04
- Earnings Announcement 2024-05-13 00:00:00
- Shares Outstanding $21,003,400
Company brief: ONCONOVA THERAPEUTICS, INC. (ONTX )
- Healthcare
- Biotechnology
- Dr. Steven M. Fruchtman M.D.
- https://www.onconova.com
- US
- N/A
- 07-25-2013
- US68232V8019
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.